Ron Feiner

Ron Feiner of JPMorgan Chase & Co. inquired about the scope of analysis for the upcoming AATD data, including which protein metrics would be reported, and asked for clarification on the assay used to measure AAT levels.

Answer

President and CEO Dr. Paul Bolno explained that the next data update will be comprehensive, covering total protein, M-protein (edited), and durability from both single and multi-dose cohorts. He emphasized the importance of longitudinal data to assess potency and duration, noting that some DNA editors have shown waning activity. Dr. Bolno confirmed that protein functionality data (elastase inhibition) would be included but did not disclose the specific assay used for total AAT measurement.

Ron Feiner of Leerink Partners inquired about the expected baseline protein levels for the WVE-006 readout, the use of DEXA scanning in the WVE-007 trial to assess muscle mass changes, and what specific DEXA signals would differentiate its 'healthy weight loss' profile from GLP-1 therapies.

Answer

President and CEO Paul Bolno explained that for WVE-006, tracking M-AAT protein is key as it's zero at baseline in ZZ patients, making it the best benchmark for editing efficiency. For WVE-007, he confirmed DEXA scans will be used to replicate preclinical findings of fat loss while sparing muscle, which would be a key differentiator from GLP-1s, though specific DEXA measurement intervals and thresholds were not disclosed.

Ron Feiner of JPMorgan Chase & Co. asked for more detail on how healthy volunteer data informs the single dose selection for the Phase Ib atopic dermatitis trial and inquired if the next immunology program would be in a new therapeutic area.

Answer

CEO Nello Mainolfi explained that the comprehensive Phase I study provides a large dataset to confidently select doses for Phase IIb, with the Phase Ib serving as a confirmatory step. Regarding the pipeline, he described Kymera's strategy of targeting complementary pathways and confirmed the new program will follow this approach.